Publications:

---

Improving HER2 testing reproducibility in HER2-low breast cancer.

Cancer Drug Resistance (Alhambra, Calif.)

Sajjadi, Elham E; Venetis, Konstantinos K; Ivanova, Mariia M; Fusco, Nicola N

Publication Date: 2022

Variant appearance in text: HER2: T798M

PubMed Link: 36627898

Variant Present in the following documents:

• cdr-5-4-882.pdf

View BVdb publication page

---

HER2 c-Terminal Fragments Are Expressed via Internal Translation of the HER2 mRNA.

International Journal Of Molecular Sciences

Godfrey, Jack D JD; Hejazi, Daniel D; Du, Xiaofei X; Wei, Cenfu C; Rao, Eshaan E; Gomez, Christopher M CM

Publication Date: 2022-08-23

Variant appearance in text: HER2: T798M

PubMed Link: 36076950

Variant Present in the following documents:

• Main text
• ijms-23-09549.pdf

View BVdb publication page

---

Understanding the activating mechanism of the immune system against COVID-19 by Traditional Indian Medicine: Network pharmacology approach.

Advances In Protein Chemistry And Structural Biology

Thirumal Kumar, D D; Shree Devi, M S MS; Udhaya Kumar, S S; Sherlin, Annie A; Mathew, Aishwarya A; Lakshmipriya, M M; Sathiyarajeswaran, P P; Gnanasambandan, R R; Siva, R R; Magesh, R R; George Priya Doss, C C

Publication Date: 2022

Variant appearance in text: ERBB2: T798M

PubMed Link: 35305722

Variant Present in the following documents:

• mmc09-01-9780323992275.pdf

View BVdb publication page

---

circCDYL2 promotes trastuzumab resistance via sustaining HER2 downstream signaling in breast cancer.

Molecular Cancer

Ling, Yun Y; Liang, Gehao G; Lin, Qun Q; Fang, Xiaolin X; Luo, Qing Q; Cen, Yinghuan Y; Mehrpour, Maryam M; Hamai, Ahmed A; Liu, Zihao Z; Shi, Yu Y; Li, Juanmei J; Lin, Wanyi W; Jia, Shijie S; Yang, Wenqian W; Liu, Qiang Q; Song, Erwei E; Li, Jun J; Gong, Chang C

Publication Date: 2022-01-03

Variant appearance in text: HER2: T798M

PubMed Link: 34980129

Variant Present in the following documents:

• 12943_2021_Article_1476.pdf

View BVdb publication page

---

Targeted Therapy of Papillary Thyroid Cancer: A Comprehensive Genomic Analysis.

Frontiers In Endocrinology

Hescheler, Daniel A DA; Riemann, Burkhard B; Hartmann, Milan J M MJM; Michel, Maximilian M; Faust, Michael M; Bruns, Christiane J CJ; Alakus, Hakan H; Chiapponi, Costanza C

Publication Date: 2021

Variant appearance in text: ERBB2: T798M

PubMed Link: 34630336

Variant Present in the following documents:

• Table_1.xlsx, sheet 2

View BVdb publication page

---

Repurposing FDA Drug Compounds against Breast Cancer by Targeting EGFR/HER2.

Pharmaceuticals (Basel, Switzerland)

Balbuena-Rebolledo, Irving I; Padilla-Martínez, Itzia Irene II; Rosales-Hernández, Martha Cecilia MC; Bello, Martiniano M

Publication Date: 2021-08-12

Variant appearance in text: HER2: T798M

PubMed Link: 34451888

Variant Present in the following documents:

• pharmaceuticals-14-00791.pdf

View BVdb publication page

---

Signaling Pathways in Cancer: Therapeutic Targets, Combinatorial Treatments, and New Developments.

Cells

Yip, Hon Yan Kelvin HYK; Papa, Antonella A

Publication Date: 2021-03-16

Variant appearance in text: HER2: T798M

PubMed Link: 33809714

Variant Present in the following documents:

• Main text

View BVdb publication page

---

Tyrosine Kinase Inhibitors Are Promising Therapeutic Tools for Cats with HER2-Positive Mammary Carcinoma.

Pharmaceutics

Gameiro, Andreia A; Almeida, Filipe F; Nascimento, Catarina C; Correia, Jorge J; Ferreira, Fernando F

Publication Date: 2021-03-06

Variant appearance in text: HER2: T798M

PubMed Link: 33800900

Variant Present in the following documents:

• Main text
• pharmaceutics-13-00346.pdf

View BVdb publication page

---

Attenuation of p53 mutant as an approach for treatment Her2-positive cancer.

Cell Death Discovery

Fedorova, Olga O; Daks, Alexandra A; Shuvalov, Oleg O; Kizenko, Alena A; Petukhov, Alexey A; Gnennaya, Yulia Y; Barlev, Nikolai N

Publication Date: 2020

Variant appearance in text: HER2: T798M

PubMed Link: 33083021

Variant Present in the following documents:

• Main text
• 41420_2020_Article_337.pdf

View BVdb publication page

---

Novel Approaches and Challenges of Discovery of Exosite Modulators of a Disintegrin and Metalloprotease 10.

Frontiers In Molecular Biosciences

Minond, Dmitriy D

Publication Date: 2020

Variant appearance in text: HER2: T798M

PubMed Link: 32435655

Variant Present in the following documents:

• fmolb-07-00075.pdf

View BVdb publication page

---

Identification of targeted therapy options for gastric adenocarcinoma by comprehensive analysis of genomic data.

Gastric Cancer : Official Journal Of The International Gastric Cancer Association And The Japanese Gastric Cancer Association

Hescheler, Daniel A DA; Plum, Patrick S PS; Zander, Thomas T; Quaas, Alexander A; Korenkov, Michael M; Gassa, Asmae A; Michel, Maximilian M; Bruns, Christiane J CJ; Alakus, Hakan H

Publication Date: 2020-07

Variant appearance in text: ERBB2: T798M

PubMed Link: 32107691

Variant Present in the following documents:

• 10120_2020_1045_MOESM1_ESM.xlsx, sheet 12

View BVdb publication page

---

An insertion mutation of ERBB2 enhances breast cancer cell growth and confers resistance to lapatinib through AKT signaling pathway.

Biology Open

Yang, Zi-Yan ZY; Yang, Liu L; Xu, Chun-Wei CW; Wang, Xiao-Jia XJ; Lei, Lei L

Publication Date: 2020-01-24

Variant appearance in text: ERBB2: T798M

PubMed Link: 31980423

Variant Present in the following documents:

• Main text
• biolopen-9-047662.pdf

View BVdb publication page

---

Identification of an Activating Mutation in the Extracellular Domain of HER2 Conferring Resistance to Pertuzumab.

Oncotargets And Therapy

Zhang, Ying Y; Wu, Shanshan S; Zhuang, Xinlei X; Weng, Gaoqi G; Fan, Jiansheng J; Yang, Xiaoyue X; Xu, Yingchun Y; Pan, Liqiang L; Hou, Tingjun T; Zhou, Zhan Z; Chen, Shuqing S

Publication Date: 2019

Variant appearance in text: HER2: T798M

PubMed Link: 31920346

Variant Present in the following documents:

• Main text

View BVdb publication page

---

Monitoring treatment efficacy and resistance in breast cancer patients via circulating tumor DNA genomic profiling.

Molecular Genetics & Genomic Medicine

Chen, Zhanhong Z; Sun, Tian T; Yang, Ziyan Z; Zheng, Yabing Y; Yu, Ruoying R; Wu, Xue X; Yan, Junrong J; Shao, Yang W YW; Shao, Xiying X; Cao, Wenming W; Wang, Xiaojia X

Publication Date: 2020-02

Variant appearance in text: ERBB2: Thr798Met

PubMed Link: 31867841

Variant Present in the following documents:

• Main text
• MGG3-8-e1079.pdf

View BVdb publication page

---

miR-200c suppresses stemness and increases cellular sensitivity to trastuzumab in HER2+ breast cancer.

Journal Of Cellular And Molecular Medicine

Tang, Hailin H; Song, Cailu C; Ye, Feng F; Gao, Guanfeng G; Ou, Xueqi X; Zhang, Lijuan L; Xie, Xinhua X; Xie, Xiaoming X

Publication Date: 2019-12

Variant appearance in text: HER2: T798M

PubMed Link: 31599500

Variant Present in the following documents:

• JCMM-23-8114.pdf

View BVdb publication page

---

Mechanism of trastuzumab resistance caused by HER-2 mutation in breast carcinomas.

Cancer Management And Research

Kong, Xiangyi X; Zhang, Kai K; Wang, Xiangyu X; Yang, Xue X; Li, Yalun Y; Zhai, Jie J; Xing, Zeyu Z; Qi, Yihang Y; Gao, Ran R; Feng, Xiaoli X; Wang, Jing J; Fang, Yi Y

Publication Date: 2019

Variant appearance in text: HER2: T798M

PubMed Link: 31308740

Variant Present in the following documents:

• Main text

View BVdb publication page

---

Identification of Genetic Mutations in Cancer: Challenge and Opportunity in the New Era of Targeted Therapy.

Frontiers In Oncology

Jin, Jing J; Wu, Xu X; Yin, Jianhua J; Li, Mingxing M; Shen, Jing J; Li, Jing J; Zhao, Yueshui Y; Zhao, Qijie Q; Wu, Jingbo J; Wen, Qinglian Q; Cho, Chi Hin CH; Yi, Tao T; Xiao, Zhangang Z; Qu, Liping L

Publication Date: 2019

Variant appearance in text: HER2: T798M

PubMed Link: 31058077

Variant Present in the following documents:

• Main text
• fonc-09-00263.pdf

View BVdb publication page

---

Prevalence and role of HER2 mutations in cancer.

Pharmacology & Therapeutics

Cocco, Emiliano E; Lopez, Salvatore S; Santin, Alessandro D AD; Scaltriti, Maurizio M

Publication Date: 2019-07

Variant appearance in text: HER2: T798M

PubMed Link: 30951733

Variant Present in the following documents:

• Main text

View BVdb publication page

---

Advances in HER2-Targeted Therapy: Novel Agents and Opportunities Beyond Breast and Gastric Cancer.

Clinical Cancer Research : An Official Journal Of The American Association For Cancer Research

Meric-Bernstam, Funda F; Johnson, Amber M AM; Dumbrava, Ecaterina E Ileana EEI; Raghav, Kanwal K; Balaji, Kavitha K; Bhatt, Michelle M; Murthy, Rashmi K RK; Rodon, Jordi J; Piha-Paul, Sarina A SA

Publication Date: 2019-04-01

Variant appearance in text: HER2: T798M

PubMed Link: 30442682

Variant Present in the following documents:

• Main text

View BVdb publication page

---

Frequency, impact and a preclinical study of novel ERBB gene family mutations in HER2-positive breast cancer.

Therapeutic Advances In Medical Oncology

Elster, Naomi N; Toomey, Sinead S; Fan, Yue Y; Cremona, Mattia M; Morgan, Clare C; Weiner Gorzel, Karolina K; Bhreathnach, Una U; Milewska, Malgorzata M; Murphy, Madeline M; Madden, Stephen S; Naidoo, Jarushka J; Fay, Joanna J; Kay, Elaine E; Carr, Aoife A; Kennedy, Sean S; Furney, Simon S; Mezynski, Janusz J; Breathhnach, Oscar O; Morris, Patrick P; Grogan, Liam L; Hill, Arnold A; Kennedy, Susan S; Crown, John J; Gallagher, William W; Hennessy, Bryan B; Eustace, Alex A

Publication Date: 2018

Variant appearance in text: HER2: T798M

PubMed Link: 30023006

Variant Present in the following documents:

• Main text
• 10.1177_1758835918778297.pdf

View BVdb publication page

---

Acquired Resistance to Drugs Targeting Tyrosine Kinases.

Advances In Cancer Research

Rosenzweig, Steven A SA

Publication Date: 2018

Variant appearance in text: HER2: T798M

PubMed Link: 29551130

Variant Present in the following documents:

• Main text

View BVdb publication page

---

Receptor tyrosine kinases (RTKs) in breast cancer: signaling, therapeutic implications and challenges.

Molecular Cancer

Butti, Ramesh R; Das, Sumit S; Gunasekaran, Vinoth Prasanna VP; Yadav, Amit Singh AS; Kumar, Dhiraj D; Kundu, Gopal C GC

Publication Date: 2018-02-19

Variant appearance in text: HER2: T798M

PubMed Link: 29455658

Variant Present in the following documents:

• Main text

View BVdb publication page

---

Genomic alterations of ERBB receptors in cancer: clinical implications.

Oncotarget

Mishra, Rosalin R; Hanker, Ariella B AB; Garrett, Joan T JT

Publication Date: 2017-12-26

Variant appearance in text: HER2: T798M

PubMed Link: 29371993

Variant Present in the following documents:

• Main text
• oncotarget-08-114371.pdf

View BVdb publication page

---

Activating HER2 mutations as emerging targets in multiple solid cancers.

Esmo Open

Connell, Claire M CM; Doherty, Gary J GJ

Publication Date: 2017

Variant appearance in text: HER2: T798M

PubMed Link: 29209536

Variant Present in the following documents:

• Main text

View BVdb publication page

---

Targeting protein quality control pathways in breast cancer.

Bmc Biology

Sannino, Sara S; Brodsky, Jeffrey L JL

Publication Date: 2017-11-16

Variant appearance in text: HER2: T798M

PubMed Link: 29145850

Variant Present in the following documents:

• 12915_2017_Article_449.pdf

View BVdb publication page

---

Impact of somatic PI3K pathway and ERBB family mutations on pathological complete response (pCR) in HER2-positive breast cancer patients who received neoadjuvant HER2-targeted therapies.

Breast Cancer Research : Bcr

Toomey, Sinead S; Eustace, Alexander J AJ; Fay, Joanna J; Sheehan, Katherine M KM; Carr, Aoife A; Milewska, Malgorzata M; Madden, Stephen F SF; Teiserskiene, Ausra A; Kay, Elaine W EW; O'Donovan, Norma N; Gallagher, William W; Grogan, Liam L; Breathnach, Oscar O; Walshe, Janice J; Kelly, Catherine C; Moulton, Brian B; Kennedy, M John MJ; Gullo, Guiseppe G; Hill, Arnold D AD; Power, Colm C; Duke, Deirdre D; Hambly, Niamh N; Crown, John J; Hennessy, Bryan T BT

Publication Date: 2017-07-27

Variant appearance in text: ERBB2: T798M

PubMed Link: 28750640

Variant Present in the following documents:

• Main text
• 13058_2017_Article_883.pdf

View BVdb publication page

---

An Acquired HER2T798I Gatekeeper Mutation Induces Resistance to Neratinib in a Patient with HER2 Mutant-Driven Breast Cancer.

Cancer Discovery

Hanker, Ariella B AB; Brewer, Monica Red MR; Sheehan, Jonathan H JH; Koch, James P JP; Sliwoski, Gregory R GR; Nagy, Rebecca R; Lanman, Richard R; Berger, Michael F MF; Hyman, David M DM; Solit, David B DB; He, Jie J; Miller, Vincent V; Cutler, Richard E RE; Lalani, Alshad S AS; Cross, Darren D; Lovly, Christine M CM; Meiler, Jens J; Arteaga, Carlos L CL

Publication Date: 2017-06

Variant appearance in text: HER2: T798M

PubMed Link: 28274957

Variant Present in the following documents:

• Main text

View BVdb publication page

---

HER2 somatic mutations are associated with poor survival in HER2-negative breast cancers.

Cancer Science

Wang, Tonghui T; Xu, Ye Y; Sheng, Shuyan S; Yuan, Hua H; Ouyang, Tao T; Li, Jinfeng J; Wang, Tianfeng T; Fan, Zhaoqing Z; Fan, Tie T; Lin, Benyao B; Xie, Yuntao Y

Publication Date: 2017-04

Variant appearance in text: HER2: T798M

PubMed Link: 28164408

Variant Present in the following documents:

• CAS-108-671.pdf

View BVdb publication page

---

Yes1 signaling mediates the resistance to Trastuzumab/Lap atinib in breast cancer.

Plos One

Takeda, Tatsuaki T; Yamamoto, Hiromasa H; Kanzaki, Hirotaka H; Suzawa, Ken K; Yoshioka, Takahiro T; Tomida, Shuta S; Cui, Xiaojiang X; Murali, Ramachandran R; Namba, Kei K; Sato, Hiroki H; Torigoe, Hidejiro H; Watanabe, Mototsugu M; Shien, Kazuhiko K; Soh, Junichi J; Asano, Hiroaki H; Tsukuda, Kazunori K; Kitamura, Yoshihisa Y; Miyoshi, Shinichiro S; Sendo, Toshiaki T; Toyooka, Shinichi S

Publication Date: 2017

Variant appearance in text: HER2: T798M

PubMed Link: 28158234

Variant Present in the following documents:

• Main text

View BVdb publication page

---

Overcoming resistance to HER2 inhibitors through state-specific kinase binding.

Nature Chemical Biology

Novotny, Chris J CJ; Pollari, Sirkku S; Park, Jin H JH; Lemmon, Mark A MA; Shen, Weijun W; Shokat, Kevan M KM

Publication Date: 2016-11

Variant appearance in text: HER2: T798M

PubMed Link: 27595329

Variant Present in the following documents:

• Main text
• nihms-796574.pdf
• NIHMS796574-supplement-1.pdf

View BVdb publication page

---

Clinical Challenges to Current Molecularly Targeted Therapies in Lung Cancer.

Archives In Cancer Research

Chhabra, Gagan G; Eggert, Ashley A; Puri, Neelu N

Publication Date: 2015

Variant appearance in text: HER2: T798M

PubMed Link: 27280107

Variant Present in the following documents:

• Main text
• nihms785107.pdf

View BVdb publication page

---

miR-30a Regulates the Expression of CAGE and p53 and Regulates the Response to Anti-Cancer Drugs.

Molecules And Cells

Park, Deokbum D; Kim, Hyuna H; Kim, Youngmi Y; Jeoung, Dooil D

Publication Date: 2016-04-30

Variant appearance in text: HER2: T798M

PubMed Link: 26912082

Variant Present in the following documents:

• Main text

View BVdb publication page

---

miR-217 and CAGE form feedback loop and regulates the response to anti-cancer drugs through EGFR and HER2.

Oncotarget

Kim, Youngmi Y; Kim, Hyuna H; Park, Deokbum D; Han, Minho M; Lee, Hansoo H; Lee, Yun Sil YS; Choe, Jongseon J; Kim, Young Myeong YM; Jeoung, Dooil D

Publication Date: 2016-03-01

Variant appearance in text: HER2: T798M

PubMed Link: 26863629

Variant Present in the following documents:

• Main text
• oncotarget-07-10297.pdf

View BVdb publication page

---

HER2-Mutated Breast Cancer Responds to Treatment With Single-Agent Neratinib, a Second-Generation HER2/EGFR Tyrosine Kinase Inhibitor.

Journal Of The National Comprehensive Cancer Network : Jnccn

Ben-Baruch, Noa Efrat NE; Bose, Ron R; Kavuri, Shyam M SM; Ma, Cynthia X CX; Ellis, Matthew J MJ

Publication Date: 2015-09

Variant appearance in text: HER2: T798M

PubMed Link: 26358790

Variant Present in the following documents:

• Main text

View BVdb publication page

---

Analysis of different HER-2 mutations in breast cancer progression and drug resistance.

Journal Of Cellular And Molecular Medicine

Sun, Zijia Z; Shi, Yaqin Y; Shen, Yan Y; Cao, Lulu L; Zhang, Wenwen W; Guan, Xiaoxiang X

Publication Date: 2015-12

Variant appearance in text: HER-2: T798M

PubMed Link: 26305917

Variant Present in the following documents:

• Main text
• JCMM-19-2691.pdf

View BVdb publication page

---

Benchmarking mutation effect prediction algorithms using functionally validated cancer-related missense mutations.

Genome Biology

Martelotto, Luciano G LG; Ng, Charlotte Ky CK; De Filippo, Maria R MR; Zhang, Yan Y; Piscuoglio, Salvatore S; Lim, Raymond S RS; Shen, Ronglai R; Norton, Larry L; Reis-Filho, Jorge S JS; Weigelt, Britta B

Publication Date: 2014-10-28

Variant appearance in text: ERBB2: T798M

PubMed Link: 25348012

Variant Present in the following documents:

• 13059_2014_484_MOESM2_ESM.xlsx, sheet 1

View BVdb publication page

---

Modulation of ErbB2 blockade in ErbB2-positive cancers: the role of ErbB2 Mutations and PHLDA1.

Plos One

Li, Guangyuan G; Wang, Xiaoqi X; Hibshoosh, Hanina H; Jin, Cheng C; Halmos, Balazs B

Publication Date: 2014

Variant appearance in text: HER2: T798M

PubMed Link: 25238247

Variant Present in the following documents:

• Main text

View BVdb publication page

---

Deregulation of the EGFR/PI3K/PTEN/Akt/mTORC1 pathway in breast cancer: possibilities for therapeutic intervention.

Oncotarget

Davis, Nicole M NM; Sokolosky, Melissa M; Stadelman, Kristin K; Abrams, Steve L SL; Libra, Massimo M; Candido, Saverio S; Nicoletti, Ferdinando F; Polesel, Jerry J; Maestro, Roberta R; D'Assoro, Antonino A; Drobot, Lyudmyla L; Rakus, Dariusz D; Gizak, Agnieszka A; Laidler, Piotr P; Dulińska-Litewka, Joanna J; Basecke, Joerg J; Mijatovic, Sanja S; Maksimovic-Ivanic, Danijela D; Montalto, Giuseppe G; Cervello, Melchiorre M; Fitzgerald, Timothy L TL; Demidenko, Zoya Z; Martelli, Alberto M AM; Cocco, Lucio L; Steelman, Linda S LS; McCubrey, James A JA

Publication Date: 2014-07-15

Variant appearance in text: HER2: T798M

PubMed Link: 25051360

Variant Present in the following documents:

• Main text

View BVdb publication page

---

Epidermal growth factor-receptor activation modulates Src-dependent resistance to lapatinib in breast cancer models.

Breast Cancer Research : Bcr

Formisano, Luigi L; Nappi, Lucia L; Rosa, Roberta R; Marciano, Roberta R; D'Amato, Claudia C; D'Amato, Valentina V; Damiano, Vincenzo V; Raimondo, Lucia L; Iommelli, Francesca F; Scorziello, Antonella A; Troncone, Giancarlo G; Veneziani, Bianca B; Parsons, Sarah J SJ; De Placido, Sabino S; Bianco, Roberto R

Publication Date: 2014-05-05

Variant appearance in text: HER2: T798M

PubMed Link: 24887236

Variant Present in the following documents:

• Main text

View BVdb publication page

---

Structure-functional prediction and analysis of cancer mutation effects in protein kinases.

Computational And Mathematical Methods In Medicine

Dixit, Anshuman A; Verkhivker, Gennady M GM

Publication Date: 2014

Variant appearance in text: ERBB2: T798M

PubMed Link: 24817905

Variant Present in the following documents:

• CMMM2014-653487.pdf

View BVdb publication page

---

Human breast cancer cells harboring a gatekeeper T798M mutation in HER2 overexpress EGFR ligands and are sensitive to dual inhibition of EGFR and HER2.

Clinical Cancer Research : An Official Journal Of The American Association For Cancer Research

Rexer, Brent N BN; Ghosh, Ritwik R; Narasanna, Archana A; Estrada, Mónica Valeria MV; Chakrabarty, Anindita A; Song, Youngchul Y; Engelman, Jeffrey A JA; Arteaga, Carlos L CL

Publication Date: 2013-10-01

Variant appearance in text: HER2: T798M

PubMed Link: 23948973

Variant Present in the following documents:

• Main text

View BVdb publication page

---

Activating Mutations in ERBB2 and Their Impact on Diagnostics and Treatment.

Frontiers In Oncology

Herter-Sprie, Grit S GS; Greulich, Heidi H; Wong, Kwok-Kin KK

Publication Date: 2013

Variant appearance in text: HER2: T798M

PubMed Link: 23630663

Variant Present in the following documents:

• Main text

View BVdb publication page

---

Molecular Mechanisms of Trastuzumab-Based Treatment in HER2-Overexpressing Breast Cancer.

Isrn Oncology

Nahta, Rita R

Publication Date: 2012

Variant appearance in text: HER2: T798M

PubMed Link: 23227361

Variant Present in the following documents:

• Main text
• ISRN.ONCOLOGY2012-428062.pdf

View BVdb publication page

---

Differential sensitivity of ERBB2 kinase domain mutations towards lapatinib.

Plos One

Kancha, Rama Krishna RK; von Bubnoff, Nikolas N; Bartosch, Natalie N; Peschel, Christian C; Engh, Richard A RA; Duyster, Justus J

Publication Date: 2011

Variant appearance in text: ERBB2: T798M

PubMed Link: 22046346

Variant Present in the following documents:

• Main text
• pone.0026760.pdf

View BVdb publication page

---